Position of Circulating Tumor Cells in the Clinical Routine in Prostate Cancer and Breast Cancer Patients
Abstract
:Simple Summary
Abstract
1. Introduction
2. Evidence Acquisition
3. Isolation Methods
4. Evidence Synthesis Prostate Cancer
4.1. CTC Enumeration—Prostate Cancer
4.2. Functional Characterization of CTCs—Prostate Cancer
5. Evidence Synthesis—Breast Cancer
5.1. CTC Enumeration—Breast Cancer
5.2. Functional Characterization of CTCs—Breast Cancer
6. Perspectives of Real-Time Monitoring
7. Discussion
8. Conclusions and Future Perspectives
Supplementary Materials
Author Contributions
Funding
Conflicts of Interest
References
- Lambert, A.W.; Pattabiraman, D.R.; Weinberg, R.A. Emerging biological principles of metastasis. Cell 2017, 168, 670–691. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Alix-Panabieres, C.; Pantel, K. Circulating tumor cells: Liquid biopsy of cancer. Clin. Chem. 2013, 59, 110–118. [Google Scholar] [CrossRef] [PubMed]
- Massague, J.; Obenauf, A.C. Metastatic colonization by circulating tumour cells. Nature 2016, 529, 298–306. [Google Scholar] [CrossRef] [PubMed]
- Welch, D.R.; Hurst, D.R. Defining the hallmarks of metastasis. Cancer Res. 2019, 79, 3011–3027. [Google Scholar] [CrossRef]
- Braun, S.; Vogl, F.D.; Naume, B.; Janni, W.; Osborne, M.P.; Coombes, R.C.; Schlimok, G.; Diel, I.J.; Gerber, B.; Gebauer, G.; et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 2005, 353, 793–802. [Google Scholar] [CrossRef] [PubMed]
- De Bono, J.S.; Scher, H.I.; Montgomery, R.B.; Parker, C.; Miller, M.C.; Tissing, H.; Doyle, G.V.; Terstappen, L.W.; Pienta, K.J.; Raghavan, D. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 2008, 14, 6302–6309. [Google Scholar] [CrossRef] [Green Version]
- Cristofanilli, M.; Budd, G.T.; Ellis, M.J.; Stopeck, A.; Matera, J.; Miller, M.C.; Reuben, J.M.; Doyle, G.V.; Allard, W.J.; Terstappen, L.W.; et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 2004, 351, 781–791. [Google Scholar] [CrossRef] [Green Version]
- Scher, H.I.; Morris, M.J.; Stadler, W.M.; Higano, C.; Basch, E.; Fizazi, K.; Antonarakis, E.S.; Beer, T.M.; Carducci, M.A.; Chi, K.N.; et al. Trial design and objectives for castration-resistant prostate cancer: Updated recommendations from the prostate cancer clinical trials working group 3. J. Clin. Oncol. 2016, 34, 1402–1418. [Google Scholar] [CrossRef] [Green Version]
- Habli, Z.; AlChamaa, W.; Saab, R.; Kadara, H.; Khraiche, M.L. Circulating tumor cell detection technologies and clinical utility: Challenges and opportunities. Cancers 2020, 12, 1930. [Google Scholar] [CrossRef]
- Ferreira, M.M.; Ramani, V.C.; Jeffrey, S.S. Circulating tumor cell technologies. Mol. Oncol. 2016, 10, 374–394. [Google Scholar] [CrossRef] [Green Version]
- Allard, W.J.; Matera, J.; Miller, M.C.; Repollet, M.; Connelly, M.C.; Rao, C.; Tibbe, A.G.; Uhr, J.W.; Terstappen, L.W. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res. 2004, 10, 6897–6904. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Swennenhuis, J.F.; van Dalum, G.; Zeune, L.L.; Terstappen, L.W. Improving the CellSearch(R) system. Expert Rev. Mol. Diagn. 2016, 16, 1291–1305. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Paoletti, C.; Hayes, D.F. Circulating tumor cells. Adv. Exp. Med. Biol. 2016, 882, 235–258. [Google Scholar] [PubMed]
- Werner, S.L.; Graf, R.P.; Landers, M.; Valenta, D.T.; Schroeder, M.; Greene, S.B.; Bales, N.; Dittamore, R.; Marrinucci, D. Analytical validation and capabilities of the epic CTC platform: Enrichment-free circulating tumour cell detection and characterization. J. Circ. Biomark. 2015, 4, 3. [Google Scholar] [CrossRef] [Green Version]
- Fachin, F.; Spuhler, P.; Martel-Foley, J.M.; Edd, J.F.; Barber, T.A.; Walsh, J.; Karabacak, M.; Pai, V.; Yu, M.; Smith, K.; et al. Monolithic chip for high-throughput blood cell depletion to sort rare circulating tumor cells. Sci. Rep. 2017, 7, 10936. [Google Scholar] [CrossRef]
- Kim, T.H.; Wang, Y.; Oliver, C.R.; Thamm, D.H.; Cooling, L.; Paoletti, C.; Smith, K.J.; Nagrath, S.; Hayes, D.F. A temporary indwelling intravascular aphaeretic system for in vivo enrichment of circulating tumor cells. Nat. Commun. 2019, 10, 1478. [Google Scholar] [CrossRef] [Green Version]
- Lianidou, E.; Pantel, K. Hellenic society of liquid biopsy. In Proceedings of the 4th ACTC | Advances in Circulating Tumor Cells, Corfu, Greece, 2–5 October 2019. [Google Scholar]
- Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef] [Green Version]
- Nuhn, P.; de Bono, J.S.; Fizazi, K.; Freedland, S.J.; Grilli, M.; Kantoff, P.W.; Sonpavde, G.; Sternberg, C.N.; Yegnasubramanian, S.; Antonarakis, E.S. Update on systemic prostate cancer therapies: Management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur. Urol. 2019, 75, 88–99. [Google Scholar] [CrossRef]
- Antonarakis, E.S.; Heath, E.I.; Posadas, E.M.; Yu, E.Y.; Harrison, M.R.; Bruce, J.Y.; Cho, S.Y.; Wilding, G.E.; Fetterly, G.J.; Hangauer, D.G.; et al. A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. Cancer Chemother. Pharmacol. 2013, 71, 883–892. [Google Scholar] [CrossRef] [Green Version]
- Goldkorn, A.; Ely, B.; Quinn, D.I.; Tangen, C.M.; Fink, L.M.; Xu, T.; Twardowski, P.; van Veldhuizen, P.J.; Agarwal, N.; Carducci, M.A.; et al. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: A phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J. Clin. Oncol. 2014, 32, 1136–1142. [Google Scholar] [CrossRef]
- Smith, M.R.; Sweeney, C.J.; Corn, P.G.; Rathkopf, D.E.; Smith, D.C.; Hussain, M.; George, D.J.; Higano, C.S.; Harzstark, A.L.; Sartor, A.O.; et al. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: Results of a phase II nonrandomized expansion study. J. Clin. Oncol. 2014, 32, 3391–3399. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Smith, M.; de Bono, J.; Sternberg, C.; le Moulec, S.; Oudard, S.; de Giorgi, U.; Krainer, M.; Bergman, A.; Hoelzer, W.; de Wit, R.; et al. Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1. J. Clin. Oncol. 2016, 34, 3005–3013. [Google Scholar] [CrossRef] [PubMed]
- Thalgott, M.; Heck, M.M.; Eiber, M.; Souvatzoglou, M.; Hatzichristodoulou, G.; Kehl, V.; Krause, B.J.; Rack, B.; Retz, M.; Gschwend, J.E.; et al. Circulating tumor cells versus objective response assessment predicting survival in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapy. J. Cancer Res. Clin. Oncol. 2015, 141, 1457–1464. [Google Scholar] [CrossRef] [PubMed]
- Vogelzang, N.J.; Fizazi, K.; Burke, J.M.; de Wit, R.; Bellmunt, J.; Hutson, T.E.; Crane, E.; Berry, W.R.; Doner, K.; Hainsworth, J.D.; et al. Circulating tumor cells in a phase 3 study of docetaxel and prednisone with or without lenalidomide in metastatic castration-resistant prostate cancer. Eur. Urol. 2017, 71, 168–171. [Google Scholar] [CrossRef]
- Heller, G.; Fizazi, K.; McCormack, R.; Molina, A.; MacLean, D.; Webb, I.J.; Saad, F.; de Bono, J.S.; Scher, H.I. The added value of circulating tumor cell enumeration to standard markers in assessing prognosis in a metastatic castration-resistant prostate cancer population. Clin. Cancer Res. 2017, 23, 1967–1973. [Google Scholar] [CrossRef] [Green Version]
- Prentice, R.L. Surrogate endpoints in clinical trials: Definition and operational criteria. Stat. Med. 1989, 8, 431–440. [Google Scholar] [CrossRef]
- Scher, H.I.; Heller, G.; Molina, A.; Attard, G.; Danila, D.C.; Jia, X.; Peng, W.; Sandhu, S.K.; Olmos, D.; Riisnaes, R.; et al. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 2015, 33, 1348–1355. [Google Scholar] [CrossRef]
- Lorente, D.; Olmos, D.; Mateo, J.; Dolling, D.; Bianchini, D.; Seed, G.; Flohr, P.; Crespo, M.; Figueiredo, I.; Miranda, S.; et al. Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts. Ann. Oncol. 2018, 29, 1554–1560. [Google Scholar] [CrossRef]
- Yu, E.Y.; Li, H.; Higano, C.S.; Agarwal, N.; Pal, S.K.; Alva, A.; Heath, E.I.; Lam, E.T.; Gupta, S.; Lilly, M.B.; et al. SWOG S0925: A randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer. J. Clin. Oncol. 2015, 33, 1601–1608. [Google Scholar] [CrossRef]
- Heller, G.; McCormack, R.; Kheoh, T.; Molina, A.; Smith, M.R.; Dreicer, R.; Saad, F.; de Wit, R.; Aftab, D.T.; Hirmand, M.; et al. Circulating tumor cell number as a response measure of prolonged survival for metastatic castration-resistant prostate cancer: A comparison with prostate-specific antigen across five randomized phase III clinical trials. J. Clin. Oncol. 2018, 36, 572–580. [Google Scholar] [CrossRef]
- Murray, N.P.; Reyes, E.; Orellana, N.; Fuentealba, C.; Badinez, L.; Olivares, R.; Porcell, J.; Duenas, R. Secondary circulating prostate cells predict biochemical failure in prostate cancer patients after radical prostatectomy and without evidence of disease. Sci. World J. 2013, 2013, 762064. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Murray, N.P.; Aedo, S.; Fuentealba, C.; Reyes, E. 10 Year Biochemical Failure Free Survival of Men with CD82 Positive Primary Circulating Prostate Cells Treated by Radical Prostatectomy. Asian Pac. J. Cancer Prev. 2018, 19, 1577–1583. [Google Scholar] [PubMed]
- Keller, L.; Pantel, K. Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nat. Rev. Cancer 2019, 19, 553–567. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gopalan, A.; Leversha, M.A.; Satagopan, J.M.; Zhou, Q.; Al-Ahmadie, H.A.; Fine, S.W.; Eastham, J.A.; Scardino, P.T.; Scher, H.I.; Tickoo, S.K.; et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res. 2009, 69, 1400–1406. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Song, C.; Chen, H. Predictive significance of TMRPSS2-ERG fusion in prostate cancer: A meta-analysis. Cancer Cell Int. 2018, 18, 177. [Google Scholar] [CrossRef]
- Danila, D.C.; Anand, A.; Sung, C.C.; Heller, G.; Leversha, M.A.; Cao, L.; Lilja, H.; Molina, A.; Sawyers, C.L.; Fleisher, M.; et al. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur. Urol. 2011, 60, 897–904. [Google Scholar] [CrossRef] [Green Version]
- Goldkorn, A.; Ely, B.; Tangen, C.M.; Tai, Y.C.; Xu, T.; Li, H.; Twardowski, P.; Veldhuizen, P.J.; Agarwal, N.; Carducci, M.A.; et al. Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase III metastatic castration resistant prostate cancer trial. Int. J. Cancer 2015, 136, 1856–1862. [Google Scholar] [CrossRef] [Green Version]
- Silver, D.A.; Pellicer, I.; Fair, W.R.; Heston, W.D.; Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 1997, 3, 81–85. [Google Scholar]
- Sweat, S.D.; Pacelli, A.; Murphy, G.P.; Bostwick, D.G. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998, 52, 637–640. [Google Scholar] [CrossRef]
- Autio, K.A.; Dreicer, R.; Anderson, J.; Garcia, J.A.; Alva, A.; Hart, L.L.; Milowsky, M.I.; Posadas, E.M.; Ryan, C.J.; Graf, R.P.; et al. Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2018, 4, 1344–1351. [Google Scholar] [CrossRef] [Green Version]
- Petrylak, D.P.; Vogelzang, N.J.; Chatta, K.; Fleming, M.T.; Smith, D.C.; Appleman, L.J.; Hussain, A.; Modiano, M.; Singh, P.; Tagawa, S.T.; et al. PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study. Prostate 2020, 80, 99–108. [Google Scholar] [CrossRef] [PubMed]
- Armstrong, A.J.; Gupta, S.; Healy, P.; Kemeny, G.; Leith, B.; Zalutsky, M.R.; Spritzer, C.; Davies, C.; Rothwell, C.; Ware, K.; et al. Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer. PLoS ONE 2019, 14, e0216934. [Google Scholar] [CrossRef] [PubMed]
- Bradley, D.A.; Daignault, S.; Ryan, C.J.; Dipaola, R.S.; Cooney, K.A.; Smith, D.C.; Small, E.; Mathew, P.; Gross, M.E.; Stein, M.N.; et al. Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium. Investig. New Drugs 2011, 29, 1432–1440. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chi, K.N.; Yu, E.Y.; Jacobs, C.; Bazov, J.; Kollmannsberger, C.; Higano, C.S.; Mukherjee, S.D.; Gleave, M.E.; Stewart, P.S.; Hotte, S.J. A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers. Ann. Oncol. 2016, 27, 1116–1122. [Google Scholar] [CrossRef] [PubMed]
- McHugh, D.; Eisenberger, M.; Heath, E.I.; Bruce, J.; Danila, D.C.; Rathkopf, D.E.; Feldman, J.; Slovin, S.F.; Anand, B.; Chu, R.; et al. A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer. Investig. New Drugs 2019, 37, 1052–1060. [Google Scholar] [CrossRef]
- Schweizer, M.T.; Haugk, K.; McKiernan, J.S.; Gulati, R.; Cheng, H.H.; Maes, J.L.; Dumpit, R.F.; Nelson, P.S.; Montgomery, B.; McCune, J.S.; et al. A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. PLoS ONE 2018, 13, e0198389. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hu, R.; Dunn, T.A.; Wei, S.; Isharwal, S.; Veltri, R.W.; Humphreys, E.; Han, M.; Partin, A.W.; Vessella, R.L.; Isaacs, W.B.; et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009, 69, 16–22. [Google Scholar] [CrossRef] [Green Version]
- Antonarakis, E.S.; Lu, C.; Wang, H.; Luber, B.; Nakazawa, M.; Roeser, J.C.; Chen, Y.; Mohammad, T.A.; Chen, Y.; Fedor, H.L.; et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 2014, 371, 1028–1038. [Google Scholar] [CrossRef] [Green Version]
- Onstenk, W.; Sieuwerts, A.M.; Kraan, J.; Van, M.; Nieuweboer, A.J.; Mathijssen, R.H.; Hamberg, P.; Meulenbeld, H.J.; de Laere, B.; Dirix, L.Y.; et al. Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells. Eur. Urol. 2015, 68, 939–945. [Google Scholar] [CrossRef]
- Antonarakis, E.S.; Lu, C.; Luber, B.; Wang, H.; Chen, Y.; Nakazawa, M.; Nadal, R.; Paller, C.J.; Denmeade, S.R.; Carducci, M.A.; et al. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer. JAMA Oncol. 2015, 1, 582–591. [Google Scholar] [CrossRef] [Green Version]
- Armstrong, A.J.; Halabi, S.; Luo, J.; Nanus, D.M.; Giannakakou, P.; Szmulewitz, R.Z.; Danila, D.C.; Healy, P.; Anand, M.; Rothwell, C.J.; et al. Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. J. Clin. Oncol. 2019, 37, 1120–1129. [Google Scholar] [CrossRef] [PubMed]
- Antonarakis, E.S.; Tagawa, S.T.; Galletti, G.; Worroll, D.; Ballman, K.; Vanhuyse, M.; Sonpavde, G.; North, S.; Albany, C.; Tsao, C.K.; et al. Randomized, noncomparative, phase II trial of early switch from docetaxel to cabazitaxel or vice versa, with integrated biomarker analysis, in men with chemotherapy-naive, metastatic, castration-resistant prostate cancer. J. Clin. Oncol. 2017, 35, 3181–3188. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kirby, B.J.; Jodari, M.; Loftus, M.S.; Gakhar, G.; Pratt, E.D.; Chanel-Vos, C.; Gleghorn, J.P.; Santana, S.M.; Liu, H.; Smith, J.P.; et al. Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. PLoS ONE 2012, 7, e35976. [Google Scholar] [CrossRef]
- Scher, H.I.; Lu, D.; Schreiber, N.A.; Louw, J.; Graf, R.P.; Vargas, H.A.; Johnson, A.; Jendrisak, A.; Bambury, R.; Danila, D.; et al. Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol. 2016, 2, 1441–1449. [Google Scholar] [CrossRef] [PubMed]
- Scher, H.I.; Graf, R.P.; Schreiber, N.A.; McLaughlin, B.; Jendrisak, A.; Wang, Y.; Lee, J.; Greene, S.; Krupa, R.; Lu, D.; et al. Phenotypic heterogeneity of circulating tumor cells informs clinical decisions between AR signaling inhibitors and taxanes in metastatic prostate cancer. Cancer Res. 2017, 77, 5687–5698. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Miyamoto, D.T.; Lee, R.J.; Kalinich, M.; LiCausi, J.A.; Zheng, Y.; Chen, T.; Milner, J.D.; Emmons, E.; Ho, U.; Broderick, K.; et al. An RNA-based digital circulating tumor cell signature is predictive of drug response and early dissemination in prostate cancer. Cancer Discov. 2018, 8, 288–303. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; Bray, F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 2015, 136, E359–E386. [Google Scholar] [CrossRef]
- Ghoncheh, M.; Pournamdar, Z.; Salehiniya, H. Incidence and Mortality and Epidemiology of Breast Cancer in the World. Asian Pac. J. Cancer Prev. 2016, 17, 43–46. [Google Scholar] [CrossRef] [Green Version]
- Tarhan, M.O.; Gonel, A.; Kucukzeybek, Y.; Erten, C.; Cuhadar, S.; Yigit, S.C.; Atay, A.; Somali, I.; Dirican, A.; Demir, L.; et al. Prognostic significance of circulating tumor cells and serum CA15-3 levels in metastatic breast cancer, single center experience, preliminary results. Asian Pac. J. Cancer Prev. 2013, 14, 1725–1729. [Google Scholar] [CrossRef] [Green Version]
- Wallwiener, M.; Hartkopf, A.D.; Baccelli, I.; Riethdorf, S.; Schott, S.; Pantel, K.; Marmé, F.; Sohn, C.; Trumpp, A.; Rack, B.; et al. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res. Treat. 2013, 137, 503–510. [Google Scholar] [CrossRef]
- Rack, B.; Schindlbeck, C.; Jückstock, J.; Andergassen, U.; Hepp, P.; Zwingers, T.; Friedl, T.W.; Lorenz, R.; Tesch, H.; Fasching, P.A.; et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J. Natl. Cancer Inst. 2014, 106, dju066. [Google Scholar] [CrossRef] [PubMed]
- Georgoulias, V.; Apostolaki, S.; Bozionelou, V.; Politaki, E.; Perraki, M.; Georgoulia, N.; Kalbakis, K.; Kotsakis, A.; Xyrafas, A.; Agelaki, S.; et al. Effect of front-line chemotherapy on circulating CK-19 mRNA-positive cells in patients with metastatic breast cancer. Cancer Chemother. Pharmacol. 2014, 74, 1217–1225. [Google Scholar] [CrossRef] [PubMed]
- Bian, L.; Liu, Y.; Wang, T.; Zhang, S.; Shao, Z.; Tong, Z.; Song, E.; Wang, X.; Liao, N.; Jiang, Z. Prediction value for dynamic changes of circulating tumor cell in therapeutic response and prognosis of Chinese metastatic breast cancer patients. Zhonghua Yi Xue Za Zhi 2014, 94, 265–268. [Google Scholar] [PubMed]
- Rugo, H.S.; Chien, A.J.; Franco, S.X.; Stopeck, A.T.; Glencer, A.; Lahiri, S.; Arbushites, M.C.; Scott, J.; Park, J.W.; Hudis, C.; et al. A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res. Treat. 2012, 134, 13–20. [Google Scholar] [CrossRef] [Green Version]
- Pierga, J.Y.; Hajage, D.; Bachelot, T.; Delaloge, S.; Brain, E.; Campone, M.; Diéras, V.; Rolland, E.; Mignot, L.; Mathiot, C.; et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann. Oncol. 2012, 23, 618–624. [Google Scholar] [CrossRef]
- Helissey, C.; Berger, F.; Cottu, P.; Diéras, V.; Mignot, L.; Servois, V.; Bouleuc, C.; Asselain, B.; Pelissier, S.; Vaucher, I.; et al. Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: The observational step of the CirCe01 phase III trial. Cancer Lett. 2015, 360, 213–218. [Google Scholar] [CrossRef]
- Smerage, J.B.; Barlow, W.E.; Hortobagyi, G.N.; Winer, E.P.; Leyland-Jones, B.; Srkalovic, G.; Tejwani, S.; Schott, A.F.; O’Rourke, M.A.; Lew, D.L.; et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J. Clin. Oncol. 2014, 32, 3483–3489. [Google Scholar] [CrossRef]
- Jiang, Z.F.; Cristofanilli, M.; Shao, Z.M.; Tong, Z.S.; Song, E.W.; Wang, X.J.; Liao, N.; Hu, X.C.; Liu, Y.; Wang, Y.; et al. Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): A multicenter, double-blind, prospective trial. Ann. Oncol. 2013, 24, 2766–2772. [Google Scholar] [CrossRef]
- Trapp, E.; Janni, W.; Schindlbeck, C.; Jückstock, J.; Andergassen, U.; de Gregorio, A.; Alunni-Fabbroni, M.; Tzschaschel, M.; Polasik, A.; Koch, J.G.; et al. Presence of circulating tumor cells in high-risk early breast cancer during follow-up and prognosis. J. Natl. Cancer Inst. 2019, 111, 380–387. [Google Scholar] [CrossRef]
- Symonds, L.; Linden, H.; Gadi, V.; Korde, L.; Rodler, E.; Gralow, J.; Redman, M.; Baker, K.; Wu, Q.V.; Jenkins, I.; et al. Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy with Bevacizumab and Erlotinib. Clin. Breast Cancer 2019, 19, e283–e296. [Google Scholar] [CrossRef]
- Manso, L.; Antón, F.M.; Perón, Y.I.; Mingorance, J.I.D.; García, P.B.; González, M.J.E.; Martínez-Jañez, N.; López-González, A.; Garate, C.O.; García, A.B.; et al. Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study. Breast J. 2019, 25, 219–225. [Google Scholar] [CrossRef] [PubMed]
- Liang, S.; Niu, L.; Xu, K.; Wang, X.; Liang, Y.; Zhang, M.; Chen, J.; Lin, M. Tumor cryoablation in combination with natural killer cells therapy and Herceptin in patients with HER2-overexpressing recurrent breast cancer. Mol. Immunol. 2017, 92, 45–53. [Google Scholar] [CrossRef] [PubMed]
- Larsson, A.M.; Jansson, S.; Bendahl, P.O.; Jörgensen, C.L.T.; Loman, N.; Graffman, C.; Lundgren, L.; Aaltonen, K.; Rydén, L. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial. Breast Cancer Res. 2018, 20, 48. [Google Scholar] [CrossRef] [PubMed]
- Hall, C.S.; Karhade, M.G.; Bauldry, J.B.B.; Valad, L.M.; Kuerer, H.M.; DeSnyder, S.M.; Lucci, A. Prognostic value of circulating tumor cells identified before surgical resection in nonmetastatic breast cancer patients. J. Am. Coll. Surg. 2016, 223, 20–29. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Goodman, C.R.; Seagle, B.L.; Friedl, T.W.P.; Rack, B.; Lato, K.; Fink, V.; Cristofanilli, M.; Donnelly, E.D.; Janni, W.; Shahabi, S.; et al. Association of circulating tumor cell status with benefit of radiotherapy and survival in early-stage breast cancer. JAMA Oncol. 2018, 4, e180163. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schramm, A.; Schochter, F.; Friedl, T.W.P.; de Gregorio, N.; Andergassen, U.; Alunni-Fabbroni, M.; Trapp, E.; Jaeger, B.; Heinrich, G.; Camara, O.; et al. Prevalence of circulating tumor cells after adjuvant chemotherapy with or without anthracyclines in patients with HER2-negative, hormone receptor-positive early breast cancer. Clin. Breast Cancer 2017, 17, 279–285. [Google Scholar] [CrossRef] [PubMed]
- Jueckstock, J.; Rack, B.; Friedl, T.W.; Scholz, C.; Steidl, J.; Trapp, E.; Tesch, H.; Forstbauer, H.; Lorenz, R.; Rezai, M.; et al. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer-Results of the German SUCCESS-A- trial. BMC Cancer 2016, 16, 401. [Google Scholar] [CrossRef] [Green Version]
- Hepp, P.; Andergassen, U.; Jäger, B.; Trapp, E.; Alunni-Fabbroni, M.; Friedl, T.W.; Hecker, N.; Lorenz, R.; Fasching, P.; Schneeweiss, A.; et al. Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer-The SUCCESS Trial. Anticancer Res. 2016, 36, 4771–4776. [Google Scholar] [CrossRef] [Green Version]
- Lelièvre, L.; Clézardin, P.; Magaud, L.; Roche, L.; Tubiana-Mathieu, N.; Tigaud, J.D.; Topart, D.; Raban, N.; Mouret-Reynier, M.A.; Mathevet, P. Comparative study of neoadjuvant chemotherapy with and without zometa for management of locally advanced breast cancer with serum VEGF as primary endpoint: The NEOZOL study. Clin. Breast Cancer 2018, 18, e1311–e1321. [Google Scholar] [CrossRef]
- Tokudome, N.; Ito, Y.; Takahashi, S.; Kobayashi, K.; Taira, S.; Tsutsumi, C.; Oto, M.; Oba, M.; Inoue, K.; Kuwayama, A.; et al. Detection of circulating tumor cells in peripheral blood of heavily treated metastatic breast cancer patients. Breast Cancer 2011, 18, 195–202. [Google Scholar] [CrossRef]
- Gonzalez-Angulo, A.M.; Lei, X.; Alvarez, R.H.; Green, M.C.; Murray, J.L.; Valero, V.; Koenig, K.B.; Ibrahim, N.K.; Litton, J.K.; Nair, L.; et al. Phase II randomized study of ixabepilone versus observation in patients with significant residual disease after neoadjuvant systemic therapy for HER2-negative breast cancer. Clin. Breast Cancer 2015, 15, 325–331. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Agelaki, S.; Kalykaki, A.; Markomanolaki, H.; Papadaki, M.A.; Kallergi, G.; Hatzidaki, D.; Kalbakis, K.; Mavroudis, D.; Georgoulias, V. Efficacy of lapatinib in therapy-resistant HER2-positive circulating tumor cells in metastatic breast cancer. PLoS ONE 2015, 10, e0123683. [Google Scholar] [CrossRef] [PubMed]
- Paoletti, C.; Schiavon, G.; Dolce, E.M.; Darga, E.P.; Carr, T.H.; Geradts, J.; Hoch, M.; Klinowska, T.; Lindemann, J.; Marshall, G.; et al. Circulating biomarkers and resistance to endocrine therapy in metastatic breast cancers: Correlative results from AZD9496 oral SERD phase I trial. Clin. Cancer Res. 2018, 24, 5860–5872. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pierga, J.Y.; Bidard, F.C.; Cropet, C.; Tresca, P.; Dalenc, F.; Romieu, G.; Campone, M.; Aït-Oukhatar, C.M.; le Rhun, E.; Gonçalves, A.; et al. Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: The LANDSCAPE trial. Ann. Oncol. 2013, 24, 2999–3004. [Google Scholar] [CrossRef]
- Babayan, A.; Hannemann, J.; Spötter, J.; Müller, V.; Pantel, K.; Joosse, S.A. Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients. PLoS ONE 2013, 8, e75038. [Google Scholar] [CrossRef] [Green Version]
- Somlo, G.; Lau, S.K.; Frankel, P.; Hsieh, H.B.; Liu, X.; Yang, L.; Krivacic, R.; Bruce, R.H. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Res. Treat. 2011, 128, 155–163. [Google Scholar] [CrossRef] [Green Version]
- Reis-Filho, J.S.; Pusztai, L. Gene expression profiling in breast cancer: Classification, prognostication, and prediction. Lancet 2011, 378, 1812–1823. [Google Scholar] [CrossRef]
- Eroles, P.; Bosch, A.; Perez-Fidalgo, J.A.; Lluch, A. Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. Cancer Treat. Rev. 2012, 38, 698–707. [Google Scholar] [CrossRef]
- Kapp, A.V.; Jeffrey, S.S.; Langerod, A.; Borresen-Dale, A.L.; Han, W.; Noh, D.Y.; Bukholm, I.R.; Nicolau, M.; Brown, P.O.; Tibshirani, R. Discovery and validation of breast cancer subtypes. BMC Genom. 2006, 7, 231. [Google Scholar] [CrossRef] [Green Version]
- Crown, J.; O’Shaughnessy, J.; Gullo, G. Emerging targeted therapies in triple-negative breast cancer. Ann. Oncol. 2012, 23 (Suppl. 6), vi56–vi65. [Google Scholar] [CrossRef]
- Jaeger, B.A.S.; Neugebauer, J.; Andergassen, U.; Melcher, C.; Schochter, F.; Mouarrawy, D.; Ziemendorff, G.; Clemens, M.; Abel, E.V.; Heinrich, G.; et al. The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial. PLoS ONE 2017, 12, e0173593. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fehm, T.; Müller, V.; Aktas, B.; Janni, W.; Schneeweiss, A.; Stickeler, E.; Lattrich, C.; Löhberg, C.R.; Solomayer, E.; Rack, B.; et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: A prospective, multicenter trial. Breast Cancer Res. Treat. 2010, 124, 403–412. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ligthart, S.T.; Bidard, F.C.; Decraene, C.; Bachelot, T.; Delaloge, S.; Brain, E.; Campone, M.; Viens, P.; Pierga, J.Y.; Terstappen, L.W. Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer. Ann. Oncol. 2013, 24, 1231–1238. [Google Scholar] [CrossRef] [PubMed]
- Ignatiadis, M.; Litière, S.; Rothe, F.; Riethdorf, S.; Proudhon, C.; Fehm, T.; Aalders, K.; Forstbauer, H.; Fasching, P.A.; Brain, E.; et al. Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): A randomized phase II trial. Ann. Oncol. 2018, 29, 1777–1783. [Google Scholar] [CrossRef]
- Azim, H.A.; Rothé, F., Jr.; Aura, C.M.; Bavington, M.; Maetens, M.; Rouas, G.; Gebhart, G.; Gamez, C.; Eidtmann, H.; Baselga, J.; et al. Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: A sub-study from the NeoALTTO phase III trial. Breast 2013, 22, 1060–1065. [Google Scholar] [CrossRef]
- Pierga, J.Y.; Petit, T.; Lévy, C.; Ferrero, J.M.; Campone, M.; Gligorov, J.; Lerebours, F.; Roché, H.; Bachelot, T.; Charafe-Jauffret, E.; et al. Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data. Clin. Cancer Res. 2015, 21, 1298–1304. [Google Scholar] [CrossRef] [Green Version]
- Konig, A.; Vilsmaier, T.; Rack, B.; Friese, K.; Janni, W.; Jeschke, U.; Andergassen, U.; Trapp, E.; Juckstock, J.; Jager, B.; et al. Determination of interleukin-4, -5, -6, -8 and -13 in serum of patients with breast cancer before treatment and its correlation to circulating tumor cells. Anticancer Res. 2016, 36, 3123–3130. [Google Scholar]
- Vilsmaier, T.; Rack, B.; König, A.; Friese, K.; Janni, W.; Jeschke, U.; Weissenbacher, T. Influence of Circulating Tumour Cells on Production of IL-1α, IL-1β and IL-12 in Sera of Patients with Primary Diagnosis of Breast Cancer Before Treatment. Anticancer Res. 2016, 36, 5227–5236. [Google Scholar] [CrossRef] [Green Version]
- Vilsmaier, T.; Rack, B.; Janni, W.; Jeschke, U.; Weissenbacher, T. Angiogenic cytokines and their influence on circulating tumour cells in sera of patients with the primary diagnosis of breast cancer before treatment. BMC Cancer 2016, 16, 547. [Google Scholar] [CrossRef] [Green Version]
- Paoletti, C.; Li, Y.; Muñiz, M.C.; Kidwell, K.M.; Aung, K.; Thomas, D.G.; Brown, M.E.; Abramson, V.G.; Irvin, W.J., Jr.; Lin, N.U.; et al. Significance of circulating tumor cells in metastatic triple-negative breast cancer patients within a randomized, phase II trial: TBCRC 019. Clin. Cancer Res. 2015, 21, 2771–2779. [Google Scholar] [CrossRef] [Green Version]
- Foroni, C.; Milan, M.; Strina, C.; Cappelletti, M.; Fumarola, C.; Bonelli, M.; Bertoni, R.; Ferrero, G.; Maldotti, M.; Takano, E.; et al. Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: Proof from the “biological window therapy”. Breast Cancer Res. Treat. 2014, 144, 113–121. [Google Scholar] [CrossRef] [PubMed]
- Smerage, J.B.; Budd, G.T.; Doyle, G.V.; Brown, M.; Paoletti, C.; Muniz, M.; Miller, M.C.; Repollet, M.I.; Chianese, D.A.; Connelly, M.C.; et al. Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer. Mol. Oncol. 2013, 7, 680–692. [Google Scholar] [CrossRef] [PubMed]
- Guan, X.; Ma, F.; Li, C.; Wu, S.; Hu, S.; Huang, J.; Sun, X.; Wang, J.; Luo, Y.; Cai, R.; et al. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer. Cancer Commun. 2019, 39, 1–10. [Google Scholar] [CrossRef] [PubMed]
- Barriere, G.; Riouallon, A.; Renaudie, J.; Tartary, M.; Rigaud, M. Mesenchymal characterization: Alternative to simple CTC detection in two clinical trials. Anticancer Res. 2012, 32, 3363–3369. [Google Scholar]
- Horimoto, Y.; Tokuda, E.; Murakami, F.; Uomori, T.; Himuro, T.; Nakai, K.; Orihata, G.; Iijima, K.; Togo, S.; Shimizu, H.; et al. Analysis of circulating tumour cell and the epithelial mesenchymal transition (EMT) status during eribulin-based treatment in 22 patients with metastatic breast cancer: A pilot study. J. Transl. Med. 2018, 16, 287. [Google Scholar] [CrossRef]
- Onstenk, W.; de Klaver, W.; de Wit, R.; Lolkema, M.; Foekens, J.; Sleijfer, S. The use of circulating tumor cells in guiding treatment decisions for patients with metastatic castration-resistant prostate cancer. Cancer Treat. Rev. 2016, 46, 42–50. [Google Scholar] [CrossRef]
- Scheel, C.; Weinberg, R.A. Cancer stem cells and epithelial-mesenchymal transition: Concepts and molecular links. Semin. Cancer Biol. 2012, 22, 396–403. [Google Scholar] [CrossRef]
- Paoletti, C.; Muniz, M.C.; Thomas, D.G.; Griffith, K.A.; Kidwell, K.M.; Tokudome, N.; Brown, M.E.; Aung, K.; Miller, M.C.; Blossom, D.L.; et al. Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer. Clin. Cancer Res. 2015, 21, 2487–2498. [Google Scholar] [CrossRef] [Green Version]
- Hashemi Goradel, N.; Najafi, M.; Salehi, E.; Farhood, B.; Mortezaee, K. Cyclooxygenase-2 in cancer: A review. J. Cell Physiol. 2019, 234, 5683–5699. [Google Scholar] [CrossRef]
- Alix-Panabieres, C. The future of liquid biopsy. Nature 2020, 579, S9. [Google Scholar] [CrossRef] [Green Version]
- Cabel, L.; Proudhon, C.; Gortais, H.; Loirat, D.; Coussy, F.; Pierga, J.Y.; Bidard, F.C. Circulating tumor cells: Clinical validity and utility. Int. J. Clin. Oncol. 2017, 22, 421–430. [Google Scholar] [CrossRef] [PubMed]
Cancer Type | Characterization | Clinical Utility of CTCs Validated in Trials | Implementation in Clinical Practice | Reference |
---|---|---|---|---|
Prostate Cancer | AR/AR-Splice Variants | Prognosis Treatment Selection Therapy Monitoring Drug resistance | requires further evaluation | [49,50,51,52,53,55] |
PSMA | Therapy monitoring | basis for future evaluation | [41,42] | |
Enumeration | Prognosis | potential clinical application | [20,21,22,23,24,25,26,27,28,29,30,31] | |
Breast Cancer | HER2 | Therapy monitoring Prognosis | basis for future evaluation basis for future evaluation | [87,94,95,96,105] [105] |
EMT | Prognosis Therapy monitoring | basis for future evaluation requires future evaluation | [104] [105] | |
Apoptosis | Therapy monitoring | basis for future evaluation | [101,102,103] | |
Enumeration | Prognosis Therapy monitoring | potential clinical application requires future evaluation basis for future evaluation requires future evaluation | [60,61] [74,97,102] [87,93,101,102,103,104,105,106] |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Theil, G.; Fornara, P.; Bialek, J. Position of Circulating Tumor Cells in the Clinical Routine in Prostate Cancer and Breast Cancer Patients. Cancers 2020, 12, 3782. https://doi.org/10.3390/cancers12123782
Theil G, Fornara P, Bialek J. Position of Circulating Tumor Cells in the Clinical Routine in Prostate Cancer and Breast Cancer Patients. Cancers. 2020; 12(12):3782. https://doi.org/10.3390/cancers12123782
Chicago/Turabian StyleTheil, Gerit, Paolo Fornara, and Joanna Bialek. 2020. "Position of Circulating Tumor Cells in the Clinical Routine in Prostate Cancer and Breast Cancer Patients" Cancers 12, no. 12: 3782. https://doi.org/10.3390/cancers12123782